scott@vtx-cpd.com

Hello again!

I wanted to share a summary of a recent multicenter study on bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, used for alleviating pain associated with osteoarthritis (OA) in dogs. I’ve highlighted the side effects section for your reference.

Study Overview
Objective: Evaluate the efficacy and safety of bedinvetmab in dogs with OA.
Design: Double-blind, randomized, multicenter, placebo-controlled study.
Participants: 287 client-owned dogs with OA.
Methods
Dogs were randomized to receive either a placebo (saline, n = 146) or bedinvetmab (0.5-1.0 mg/kg, n = 141) administered monthly. After three months, dogs that responded positively to bedinvetmab continued to receive the treatment in an open-label phase.

Results
Efficacy:

Treatment success was significantly higher in the bedinvetmab group compared to the placebo group from day 7 through all assessed time points.
By day 28, 43.5% of dogs treated with bedinvetmab achieved treatment success compared to 16.9% in the placebo group (p = 0.0017).
This success continued through days 56 (50.8%) and 84 (48.2%) in the bedinvetmab group, with less than 25% success in the placebo group.
Sustained efficacy was demonstrated in the continuation phase.
Safety:

Adverse health events (AHEs) occurred at similar frequencies in both the bedinvetmab and placebo groups and were typical for a population of dogs with OA, often associated with comorbidities.
The most frequently reported AHEs were musculoskeletal disorders, including joint pain and lameness, with joint pain being more common in the placebo group.
During the study, two dogs in the placebo group and one dog in the bedinvetmab group died, but the deaths were not related to the study treatment.
Common AHEs included digestive tract disorders, systemic disorders, skin disorders, and respiratory tract disorders, with some variations between the placebo and bedinvetmab groups.
A mild transient injection site reaction was observed in one dog in each group, complicated by underlying pre-existing atopy.

Conclusions
The study demonstrated the effectiveness and safety of bedinvetmab administered monthly for up to nine months at 0.5-1.0 mg/kg for alleviating pain associated with canine osteoarthritis.

Side Effects Highlight
Musculoskeletal disorders: Joint pain and lameness were reported, with joint pain more common in the placebo group.
Digestive tract disorders: Emesis and diarrhea were noted.
Systemic disorders: Lethargy and anorexia were observed.
Skin and appendages disorders: Alopecia and pruritus were reported.
Respiratory tract disorders: Cough and tachypnea occurred.
Renal and urinary disorders: Polyuria and urinary incontinence were observed.
Neurological disorders: Proprioception abnormality and paresis were reported but were not common.

Just some more evidence to share with clients!

Best,

Scott 🙂

Hi Rosanna,

For small animal internal medicine, I highly recommend “Ettinger’s Textbook of Veterinary Internal Medicine.” It’s widely considered the go-to resource in the field. There is a new edition available, which is quite comprehensive and detailed. It’s a two-volume text, so it is heavy-duty, but it also includes online access, which is a great bonus.

You can find the latest edition here: https://www.evolve.elsevier.com/cs/product/9780323779319?role=student

This textbook is often referred to as the “Internal Medicine Bible,” and it’s definitely the one I would go for if you’re looking for the most up-to-date and thorough resource. However, if you’re looking for something a bit more quick-fire and practical, I can make other recommendations. It would also be interesting to hear other people’s thoughts on this.

This is definitely the most comprehensive text, with the benefit of being quite an up-to-date version. As you know, textbooks can become outdated quickly, so having the latest edition is crucial.

Best regards,

Scott 🙂